Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): The final results from a phase II single-arm trial.

被引：4

作者：

Kong, Tiandong ^{[1
]}

Chen, Lu ^{[1
]}

Duan, Fangfang ^{[1
]}

Hou, Xiaoxia ^{[1
]}

Wang, Liuyan ^{[1
]}

Zhou, Hanli ^{[1
]}

Wang, Lanrong ^{[1
]}

Hu, Shanshan ^{[1
]}

Liu, Danna ^{[1
]}

机构：

[1] Henan Univ, Peoples Hosp Zhengzhou City 3, Canc Hosp, Zhengzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.8560

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8560

引用

下载

页数：3

共 50 条

[1] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
Kong, Tiandong
Chen, Lu
Zhao, Xiaoli
Duan, Fangfang
Zhou, Hanli
Wang, Lei
Liu, Danna
INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1095 - 1105
[2] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
Tiandong Kong
Lu Chen
Xiaoli Zhao
Fangfang Duan
Hanli Zhou
Lei Wang
Danna Liu
Investigational New Drugs, 2022, 40 : 1095 - 1105
[3] The efficacy and safety profile of anlotinib with etoposide plus cisplatin/carboplatin in treatment-naive extensive-stage small cell lung cancer(SCLC) patients: Results from a phase II single-arm trial.
Deng, Pengbo
Yang, Huaping
Chen, Cen
Hu, Chengping
Cao, Liming
Gu, Qihua
An, Jian
Li, Bin
Tang, Yongjun
Meng, Jie
Feng, Juntao
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[4] Anlotinib Plus Etoposide and Carboplatin as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: A Single Arm Phase II Trial
Han, B.
Zhang, W.
Zhang, B.
Chen, Y.
Zhang, Y.
Lou, Y.
Dong, Y.
Qian, F.
Zhou, W.
Yang, Z.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S503 - S503
[5] Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial
Deng, Pengbo
Hu, Chengping
Chen, Cen
Cao, Liming
Gu, Qihua
An, Jian
Qin, Ling
Li, Min
He, Baimei
Jiang, Juan
Yang, Huaping
CANCER MEDICINE, 2022, 11 (19): : 3563 - 3571
[6] Efficacy and safety analysis of anlotinib and durvalumab plus chemotherapy in first-line therapy extensive-stage small cell lung cancer (SCLC)
Chen, L.
Zhao, Y.
Wu, H.
Hu, X.
Wu, H.
ANNALS OF ONCOLOGY, 2022, 33 : S1580 - S1580
[7] First-Line Envafolimab plus Carboplatin-etoposide in Extensive-Stage Small-Cell Lung Cancer: a Single-Arm Phase II Study
Sun, S.
Zhao, X.
Zhang, J.
Zhang, X.
Han, Q.
Yan, X.
Zhu, Y.
Wang, J.
Jiao, S.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S371 - S371
[8] Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial.
Chen, Dawei
Zou, Bing
Meng, Xiangjiao
Huang, Wei
Shao, Qian
Tang, Xiaoyong
Guo, Jun
Hu, Xudong
Zhang, Yan
Fu, Lei
Yuan Jiajia
Yu, Jinming
Wang, Linlin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial
Wu, Yuan
Zhou, Xuefeng
Zhao, Weiqing
Wang, Qiong
Han, Zhengxiang
Wang, Lifeng
Zhou, Wenjie
Zhou, Tong
Song, Haizhu
Chen, Yong
Yang, Kaihua
Shi, Lin
Pan, Banzhou
Guo, Renhong
Zhou, Guoren
Jiang, Feng
Feng, Jifeng
Shen, Bo
INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 825 - 833
[10] Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial
Yuan Wu
Xuefeng Zhou
Weiqing Zhao
Qiong Wang
Zhengxiang Han
Lifeng Wang
Wenjie Zhou
Tong Zhou
Haizhu Song
Yong Chen
Kaihua Yang
Lin Shi
Banzhou Pan
Renhong Guo
Guoren Zhou
Feng Jiang
Jifeng Feng
Bo Shen
Investigational New Drugs, 2023, 41 : 825 - 833

← 1 2 3 4 5 →